Bj. Steinberg et al., DEPRESSIVE RESPONSE TO PHYSOSTIGMINE CHALLENGE IN BORDERLINE PERSONALITY-DISORDER PATIENTS, Neuropsychopharmacology, 17(4), 1997, pp. 264-273
The purpose of this study was to examine the relationship between mood
and hormonal responses to cholinergic challenge with physostigmine in
order to assess cholinergic system responsiveness in borderline perso
nality disorder (BPD) patients, other non-BPD personality disorder pat
ients, and normal controls. Thirty-four personality disorder patients,
10 of whom met criteria for BPD and 24 of whom met criteria for other
, non-borderline, personality disorders, and II normal controls partic
ipated in a double blind, placebo controlled physostigmine challenge p
aradigm. The Profile of Mood States depression subscale (POMS-D) self
report measure was obtained at baseline and following the physostigmin
e or placebo infusions. A repeated measures ANOVA of POMS-D scores in
placebo and drug conditions indicated a significantly greater depressi
ve response in the total cohort of personality disorder patients than
in the normal comparison group (p < 0.05). However, the depressive res
ponse to physostigmine was significantly greater in BPD patients, but
not other personality disorder patients, compared to normal controls (
p < 0.05). There was a correlation between the peak placebo-corrected
depressive response to physostigmine and a group of BPD traits related
to affective instability but not a group of BPD traits related to imp
ulsivity. There was no correlation in any group between mood response
to physostigmine and changes in plasma cortisol, prolactin, or growth
hormone, or to nausea or other side effects following physostigmine in
fusion. These data suggest that there is an association between BPD an
d acute depressive responses to physostigmine challenge, and that the
cholinergic system may be involved in the regulation of affect in Axis
II disorders. Published by Elsevier Science Inc.